Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes.
Sobral-Leite M, Salomon I, Opdam M, Kruger DT, Beelen KJ, van der Noort V, van Vlierberghe RLP, Blok EJ, Giardiello D, Sanders J, Van de Vijver K, Horlings HM, Kuppen PJK, Linn SC, Schmidt MK, Kok M. Sobral-Leite M, et al. Among authors: kruger dt. Breast Cancer Res. 2019 Aug 7;21(1):90. doi: 10.1186/s13058-019-1176-2. Breast Cancer Res. 2019. PMID: 31391067 Free PMC article.
Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature.
Opdam M, van der Noort V, Kleijn M, Glas A, Mandjes I, Kleiterp S, Hilbers FS, Kruger DT, Bins AD, de Jong PC, Schiphorst PPJBM, van Dalen T, Flameling B, Rietbroek RC, Beeker A, van den Heiligenberg SM, Bakker SD, Wymenga ANM, Oving IM, Bijlsma RM, van Diest PJ, Vermorken JB, van Tinteren H, Linn SC. Opdam M, et al. Among authors: kruger dt. Breast Cancer Res Treat. 2022 Jul;194(2):265-278. doi: 10.1007/s10549-022-06618-z. Epub 2022 May 19. Breast Cancer Res Treat. 2022. PMID: 35587322 Free PMC article. Clinical Trial.
MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer.
Bhin J, Yemelyanenko J, Chao X, Klarenbeek S, Opdam M, Malka Y, Hoekman L, Kruger D, Bleijerveld O, Brambillasca CS, Sprengers J, Siteur B, Annunziato S, van Haren MJ, Martin NI, van de Ven M, Peters D, Agami R, Linn SC, Boven E, Altelaar M, Jonkers J, Zingg D, Wessels LFA. Bhin J, et al. J Exp Med. 2023 Nov 6;220(11):e20211743. doi: 10.1084/jem.20211743. Epub 2023 Aug 29. J Exp Med. 2023. PMID: 37642941 Free PMC article.